Anti-Cortactin Autoantibodies Are Associated With Key Clinical Features in Adult Myositis But Are Rarely Present in Juvenile Myositis.
Journal
Arthritis & rheumatology (Hoboken, N.J.)
ISSN: 2326-5205
Titre abrégé: Arthritis Rheumatol
Pays: United States
ID NLM: 101623795
Informations de publication
Date de publication:
02 2022
02 2022
Historique:
revised:
15
06
2021
received:
20
09
2020
accepted:
22
06
2021
pubmed:
28
7
2021
medline:
19
2
2022
entrez:
27
7
2021
Statut:
ppublish
Résumé
To define the prevalence and clinical phenotype of anti-cortactin autoantibodies in adult and juvenile myositis. In this longitudinal cohort study, anti-cortactin autoantibody titers were assessed by enzyme-linked immunosorbent assay in 670 adult myositis patients and 343 juvenile myositis patients as well as in 202 adult healthy controls and 90 juvenile healthy controls. The prevalence of anti-cortactin autoantibodies was compared among groups. Clinical features of patients with and those without anti-cortactin autoantibodies were also compared. Anti-cortactin autoantibodies were more common in adult dermatomyositis (DM) patients (15%; P = 0.005), particularly those with coexisting anti-Mi-2 autoantibodies (24%; P = 0.03) or anti-NXP-2 autoantibodies (23%; P = 0.04). In adult myositis, anti-cortactin was associated with DM skin involvement (62% of patients with anti-cortactin versus 38% of patients without anti-cortactin; P = 0.03), dysphagia (36% versus 17%; P = 0.02) and coexisting anti-Ro 52 autoantibodies (47% versus 26%; P = 0.001) or anti-NT5c1a autoantibodies (59% versus 33%; P = 0.001). Moreover, the titers of anti-cortactin antibodies were higher in patients with interstitial lung disease (0.15 versus 0.12 arbitrary units; P = 0.03). The prevalence of anti-cortactin autoantibodies was not different in juvenile myositis patients (2%) or in any juvenile myositis subgroup compared to juvenile healthy controls (4%). Nonetheless, juvenile myositis patients with these autoantibodies had a higher prevalence of "mechanic's hands" (25% versus 7%; P = 0.03), a higher number of hospitalizations (2.9 versus 1.3; P = 0.04), and lower peak creatine kinase values (368 versus 818 IU/liter; P = 0.02) than those without anti-cortactin. The prevalence of anti-cortactin autoantibodies is increased in adult DM patients with coexisting anti-Mi-2 or anti-NXP-2 autoantibodies. In adults, anti-cortactin autoantibodies are associated with dysphagia and interstitial lung disease.
Identifiants
pubmed: 34313394
doi: 10.1002/art.41931
pmc: PMC8792092
mid: NIHMS1727480
doi:
Substances chimiques
Autoantibodies
0
Cortactin
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
358-364Subventions
Organisme : Intramural NIH HHS
ID : ZIA AR041203
Pays : United States
Organisme : NIAMS NIH HHS
Pays : United States
Organisme : NIEHS NIH HHS
Pays : United States
Organisme : Myositis Association
Investigateurs
Heinrike Schmeling
(H)
Bita Arabshahi
(B)
Imelda Balboni
(I)
Susan Ballinger
(S)
Lilliana Barillas-Arias
(L)
Mara Becker
(M)
Catherine April Bingham
(CA)
John F Bohnsack
(JF)
Ruy Carrasco
(R)
Victoria Cartwright
(V)
Gail D Cawkwell
(GD)
Rodolfo Curiel
(R)
Jason Dare
(J)
Marietta M DeGuzman
(MM)
Kaleo Eade
(K)
Barbara Anne Ebernardt
(BA)
Barbara S Edelheit
(BS)
Moussa El-Hallak
(M)
Terri H Finkel
(TH)
Stephen W George
(SW)
Ellen A Goldmuntz
(EA)
Beth Gottlieb
(B)
Brent Graham
(B)
William Hannan
(W)
Michael Henrickson
(M)
Gloria C Higgins
(GC)
Patricia Hobday
(P)
Alice Hoftman
(A)
Sandy Hong
(S)
Adam Huber
(A)
Lisa Imundo
(L)
Christi Inman
(C)
Anna Jansen
(A)
James Jarvis
(J)
Lawrence Jung
(L)
Philip Kahn
(P)
Ildy M Katona
(IM)
Yukiko Kimura
(Y)
Daniel J Kingsbury
(DJ)
W Patrick Knibbe
(WP)
Bianca A Lang
(BA)
Maureen Leffler
(M)
Melissa Lerman
(M)
Carol B Lindsley
(CB)
Katherine L Madson
(KL)
Gulnara Mamyrova
(G)
Diana Milojevic
(D)
Stephen R Mitchell
(SR)
Renee Modica
(R)
Linda Myers
(L)
Kabita Nanda
(K)
Simona Nativ
(S)
Terrance O'Hanlon
(T)
Judyann C Olson
(JC)
Lauren M Pachman
(LM)
Murray H Passo
(MH)
Maria D Perez
(MD)
Donald A Person
(DA)
Marilyn G Punaro
(MG)
Linda I Ray
(LI)
Robert M Rennebohm
(RM)
Rafael F Rivas-Chacon
(RF)
Tova Ronis
(T)
Margalit Rosenkranz
(M)
Deborah Rothman
(D)
Adam Schiffenbauer
(A)
Bracha Shaham
(B)
Susan Shenoi
(S)
David Sherry
(D)
David Siegel
(D)
Abigail Smukler
(A)
Jennifer Soep
(J)
Matthew Stoll
(M)
Sangeeta H Sule
(SH)
Robert Sundel
(R)
Stacey Tarvin
(S)
Melissa Tesher
(M)
Scott A Vogelgesang
(SA)
Rita Volochayev
(R)
Dawn Wahezi
(D)
Jennifer C Wargula
(JC)
Peter Weiser
(P)
Pamela Weiss
(P)
Patience H White
(PH)
Andrew Zeft
(A)
Lawrence S Zemel
(LS)
Yongdong Zhao
(Y)
Informations de copyright
© 2021 American College of Rheumatology. This article has been contributed to by US Government employees and their work is in the public domain in the USA.
Références
Semin Arthritis Rheum. 2012 Jun;41(6):890-9
pubmed: 22078416
Mem Inst Oswaldo Cruz. 2016 Jul 4;111(8):501-4
pubmed: 27384081
Rheumatology (Oxford). 2017 Jun 1;56(6):999-1007
pubmed: 28339994
Arthritis Rheum. 2006 Nov;54(11):3682-9
pubmed: 17075819
Arthritis Rheum. 2011 Mar;63(3):713-21
pubmed: 21360500
Ann Rheum Dis. 2019 Jul;78(7):988-995
pubmed: 31018961
Nat Rev Rheumatol. 2018 Apr 20;14(5):290-302
pubmed: 29674612
Medicine (Baltimore). 2013 Jan;92(1):25-41
pubmed: 23263716
Neurology. 2014 Jul 29;83(5):426-33
pubmed: 24975859
Arthritis Care Res (Hoboken). 2017 Nov;69(11):1771-1776
pubmed: 28085235
Autoimmun Rev. 2014 Oct;13(10):1003-7
pubmed: 25193850
Ann Rheum Dis. 2018 May;77(5):714-719
pubmed: 29363513
Ann Neurol. 1995 Nov;38(5):705-13
pubmed: 7486861
Autoimmun Rev. 2014 Oct;13(10):1008-12
pubmed: 25182205
N Engl J Med. 1975 Feb 13;292(7):344-7
pubmed: 1090839
J Am Acad Dermatol. 2002 Apr;46(4):626-36
pubmed: 11907524
Medicine (Baltimore). 2013 Jul;92(4):223-243
pubmed: 23877355
J Neurol Neurosurg Psychiatry. 2016 Apr;87(4):373-8
pubmed: 25857661
Am J Respir Crit Care Med. 2013 Sep 15;188(6):733-48
pubmed: 24032382
Lancet Neurol. 2018 Sep;17(9):816-828
pubmed: 30129477